Profund Advisors LLC Cyma Bay Therapeutics, Inc. Transaction History

Profund Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $92,224 - $178,679	7,302 Added 38.51%	26,263 $620,000
Q3 2023 Nov 13, 2023	SELL	$10.86 - $17.62 $8,579 - $13,919	-790 Reduced 4.0%	18,961 $282,000
Q2 2023 Aug 10, 2023	BUY	$7.47 - $10.95 $48,913 - $71,700	6,548 Added 49.59%	19,751 $216,000
Q1 2023 May 11, 2023	BUY	$5.88 - $9.59 $77,633 - $126,616	13,203 New	13,203 $115,000
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $147,418 - $242,445	-18,066 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $22,746 - $40,831	-3,478 Reduced 16.14%	18,066 $142,000
Q3 2018 Nov 13, 2018	BUY	$10.88 - $14.52 $234,398 - $312,818	21,544 New	21,544 $239,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Profund Advisors LLC with notifications on news.